Clinical trials: Stage III Skin Cancer
Advanced Breast Cancer
Phase II Dasatinib Study in Advanced Breast Cancer
The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.
- Trial name
- NCT00546104
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer, Contralateral Breast Cancer
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may improve the ability to detect cancer in the unaffected breast of women recently diagnosed with unilateral breast cancer.
- Trial name
- ACRIN-6667 (NCT00058058)
- Testing
- MRI
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 1,007 people
- Sponsor
- American College of Radiology Imaging Network
Recurrent Melanoma, Stage IIIc Melanoma
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
- Trial name
- NCT01316692
- Testing
- laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced, Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- MONALEESA-2 (NCT01958021)
- Testing
- Ribociclib, Letrozole
- Where
- 221 sites in United States, Argentina and 27 more
- Volunteers
- 668 people
- Sponsor
- Novartis Pharmaceuticals
Stage III Melanoma, Stage IV Melanoma
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
This is a Phase II single-arm, open-label, clinical trial evaluating the efficacy and safety of pazopanib in combination with paclitaxel as first line therapy for subjects with unresectable Stage III and Stage IV melanoma.
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
- Trial name
- NCT01107665
- Testing
- Pazopanib and Paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Breast Cancer
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.
- Trial name
- NCT00824733
- Testing
- Trastuzumab, PF03512676, Correlative Studies
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bhuvaneswari Ramaswamy
Bone Pain in Stage I - III Breast Cancer
NOLAN: Naproxen or Loratadine and Neulasta
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic…
- Trial name
- NOLAN (NCT01712009)
- Testing
- Naproxen, Loratadine, Pegfilgrastim
- Where
- 83 sites in United States
- Volunteers
- 600 people
- Sponsor
- Amgen
Melanoma Stage Iii, Melanoma Stage Iv
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1…
- Conditions
- Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin)
- Trial name
- NCT03620019
- Testing
- Denosumab, Pembrolizumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer.
- Conditions
- Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Trial name
- NCT02883062
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Malignant Melanoma
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.
- Trial name
- COMBI-APlus (NCT03551626)
- Testing
- Dabrafenib, Trametinib
- Where
- 100 sites in Argentina, Australia and 21 more
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Lymph Node Cancer
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
- Trial name
- NCT03618641
- Testing
- CMP-001, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Diwakar Davar
Breast Cancer
PALbociclib CoLlaborative Adjuvant Study
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early…
- Trial name
- PALLAS (NCT02513394)
- Testing
- Palbociclib, Standard Adjuvant Endocrine Therapy
- Where
- 437 sites in United States, Australia and 19 more
- Volunteers
- 5,796 people
- Sponsor
- Alliance Foundation Trials, LLC.
Breast Cancer
Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
This trial tests surgical oophorectomy (removal of ovaries) plus Tamoxifen, done at different times in the menstrual cycle, as adjuvant therapy for invasive breast cancer in 510 premenopausal women with Hormone Receptor-positive…
- Trial name
- NCT00201851
- Testing
- Tamoxifen, Surgery: Oophorectomy
- Where
- 9 sites in Morocco, Philippines and 1 more
- Volunteers
- 740 people
- Sponsor
- International Breast Cancer Research Foundation
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.
- Trial name
- NCT00088829
- Testing
- paclitaxel, microarray analysis, biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Breast Cancer, Metastatic Breast Cancer
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast…
- Trial name
- NCT00404066
- Testing
- Lapatinib, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- George Albert Fisher
Breast Cancer
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093795
- Testing
- Cyclophosphamide, Docetaxel, Gemcitabine
- Where
- 12 sites in United States
- Volunteers
- 4,894 people
- Sponsor
- NSABP Foundation Inc
Cancer, Breast, Inflammation
Hypofractionated Radiotherapy in Breast Cancer
As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation…
- Trial name
- NCT03167359
- Testing
- Hypofractionated Simultaneous Integrated Boost Radiotherapy
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Emory University